Table 1.
Disease-modifying antirheumatic drug (DMARD) therapy
| AZ | |||||||||||
| csDMARD | bDMARD | tsDMARD | |||||||||
| Withhold (n) | Continue (n) | Withhold (n) | Continue (n) | Withhold (n) | Continue (n) | ||||||
| MTX | 7 | MTX | 9 | ADA | 3 | ADA | 2 | BARI | 3 | BARI | 1 |
| MTX+HCQ | 2 | MTX+HCQ | 3 | ETA | 2 | ETA | 1 | TOF | 4 | TOF | 3 |
| MTX+SSZ | 2 | SSZ | 1 | GOL | 1 | GOL | 2 | TOF+MTX | 3 | TOF+MTX | 3 |
| MTX+IXE | 0 | MTX+IXE | 1 | IXE | 2 | IXE | 3 | UPA | 5 | UPA | 8 |
| MTX+SEC | 0 | MTX+SEC | 1 | SEC | 2 | SEC | 3 | ||||
| MTX+TOC | 1 | MTX+TOC | 1 | TOC | 1 | TOC | 4 | ||||
| UST | 0 | UST | 2 | ||||||||
| Total | 12 | 16 | 11 | 17 | 15 | 15 | |||||
| Pfizer | |||||||||||
| csDMARD | bDMARD | tsDMARD | |||||||||
| Withhold (n) | Continue (n) | Withhold (n) | Continue (n) | Withhold (n) | Continue (n) | ||||||
| LEF | 1 | LEF | 1 | ADA | 4 | ADA | 5 | BARI | 4 | BARI | 4 |
| MTX | 7 | MTX | 8 | CTZ | CTZ | 2 | BARI+MTX | 1 | BARI+MTX | 1 | |
| MTX+HCQ | 4 | MTX+HCQ | 3 | ETA | 1 | ETA | 1 | TOF | 3 | TOF | 2 |
| MTX+SSZ | 1 | MTX+SSZ | 3 | GOL | 0 | GOL | 1 | TOF+MTX | 0 | TOF+MTX | 0 |
| MTX+ETA | 0 | MTX+ETA | 1 | GUS | 1 | GUS | 0 | UPA | 7 | UPA | 7 |
| MTX+SEC | 1 | MTX+SEC | 0 | INF | 1 | INF | 1 | UPA+MTX | 0 | UPA+MTX | 1 |
| MTX+TOC | 0 | MTX+TOC | 0 | IXE | 4 | IXE | 5 | ||||
| SEC | 2 | SEC | 1 | ||||||||
| TOC | 2 | TOC | 2 | ||||||||
| UST | 0 | UST | 1 | ||||||||
| Total | 14 | 16 | 15 | 20 | 15 | 15 | |||||
MTX, methotrexate; HCQ, hydroxychloroquine; SSZ, sulfasalazine; LEF, leflunamide; ADA, adalimumab; CTZ, certolizumab; ETA, etanercept; GOL, golimumab; GUS, guselkumab; INF, infliximab; IXE, ixekizumab; SEC, secukinumab, TOC, tocilizumab, UST, ustekinumab; BARI, baricitinib; TOF, tofacitinib; UPA, upadacitinib.
ADA, adalimumab; BARI, baricitinib; bDMARD, biologic DMARD; csDMARD, conventional synthetic DMARD; CTZ, certolizumab; ETA, etanercept; GOL, golimumab; GUS, guselkumab; HCQ, hydroxychloroquine; INF, infliximab; IXE, ixekizumab; LEF, leflunamide; MTX, methotrexate; SEC, secukinumab; SSZ, sulfasalazine; TOC, tocilizumab; TOF, tofacitinib; tsDMARD, targeted synthetic DMARD; UPA, upadacitinib; UST, ustekinumab.